| [1] |
何山, 田庄, 任超, 等. 转甲状腺素蛋白淀粉样变心肌病的规范化诊断[J]. 中国实用内科杂志, 2020, 40(12):978-980,989.
|
| [2] |
Bistola V, Parissis J, Foukarakis E, et al. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis[J]. Heart Fail Rev, 2021, 26(4):861-879.
|
| [3] |
Fontana M, Ćorović A, Scully P, et al. Myocardial amyloidosis: the exemplar interstitial disease[J]. JACC Cardiovasc Imaging, 2019, 12(11 Pt 2):2345-2356.
|
| [4] |
Giblin GT, Cuddy S, González-López E, et al. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(8):1029-1039.
|
| [5] |
Li H, Rozenbaum M, Casey M, et al. Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death[J]. Cardiology, 2022, 147(4):398-405.
|
| [6] |
Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction[J]. JACC Heart Fail, 2014, 2(2):113-122.
|
| [7] |
Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)[J]. Am Heart J, 2012, 164(2):222-228.
|
| [8] |
Rigopoulos AG, Ali M, Abate E, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement[J]. Heart Fail Rev, 2019, 24(4):521-533.
|
| [9] |
AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction[J]. JAMA Cardiol, 2021, 6(11):1267-1274.
|
| [10] |
González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction[J]. Eur Heart J, 2015, 36(38):2585-2594.
|
| [11] |
Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system[J]. J Am Coll Cardiol, 2016, 68(10):1014-1020.
|
| [12] |
Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway[J]. Proc Natl Acad Sci U S A, 2010, 107(9):4188-4193.
|
| [13] |
Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts[J]. Circulation, 2001, 104(14):1594-1597.
|
| [14] |
Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review[J]. Cardiol Ther, 2021, 10(1):141-159.
|
| [15] |
Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade[J]. Proc Natl Acad Sci U S A, 2012, 109(24):9629-9634.
|
| [16] |
Oghina S, Josse C, Bézard M, et al. Prognostic value of N-terminal pro-Brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment[J]. J Clin Med, 2021, 10(21):4868.
|